Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22792229 | 0.82 | CTSA (0.48) | CTSAKDM4EALDH1A1HCAR3PDPK1 | |
| SCHEMBL69399 | 0.78 | KDM4E (0.55) | KDM4EALDH1A1HCAR2NAPRTLMNA | |
| SCHEMBL8065855 | 0.75 | FYN (0.43) | CTSAKDM4EALDH1A1HCAR3PDPK1 | |
| SCHEMBL6270179 | 0.74 | BAZ2B (0.42) | CTSAPDPK1NNMTFYN | |
| SCHEMBL287705 | 0.72 | GRM5 (0.46) | KDM4EALDH1A1HCAR2NAPRTGRM5 | |
| SCHEMBL20929039 | 0.72 | KDM4E (0.45) | KDM4EALDH1A1HCAR2NAPRTLMNA | |
| SCHEMBL30951916 | 0.72 | KDM4E (0.68) | KDM4EHCAR3NAPRTLMNAGRM5 | |
| SCHEMBL27881336 | 0.72 | KDM4E (0.49) | KDM4EALDH1A1HCAR2NAPRTALOX15 | |
| SCHEMBL3117402 | 0.72 | KDM4E (0.68) | KDM4EHCAR3NAPRTLMNAGRM5 | |
| SCHEMBL186538 | 0.72 | HCAR3 (0.36) | CTSAKDM4EALDH1A1HCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021118485-A1 | A PRODUCTION METHOD OF BIOACTIVE SUBSTANCE THYMOKINONE BY USING AY-YLDIZ CATALYST WHITH USE POTENTIAL IN CANCER TREATMENT | CUKUROVA UNIVERSITESI REKTORLUGU (TR) | 2021-06-17 | — | — | WO | claimed |
| EP-4617265-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Prime Gene Therapeutics Co., Ltd. (CN) | 2025-09-17 | — | — | EP | disclosed |
| CN-120202197-A | Nitrogen-containing spiro compound, pharmaceutical composition and application thereof | 北京普祺医药科技股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2024099404-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2024-05-16 | — | — | WO | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| WO-2021118485-A1 | A PRODUCTION METHOD OF BIOACTIVE SUBSTANCE THYMOKINONE BY USING AY-YLDIZ CATALYST WHITH USE POTENTIAL IN CANCER TREATMENT | CUKUROVA UNIVERSITESI REKTORLUGU (TR) | 2021-06-17 | — | — | WO | disclosed |
| CN-102414177-B | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT | 2014-07-02 | — | — | CN | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| CN-102414177-A | Compounds as bradykinin b1 antagonists | BOEHRINGER INGELHEIM INT | 2012-04-11 | — | — | CN | disclosed |
| EP-2401256-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| CN-1296346-C | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-01-24 | — | — | CN | disclosed |
| US-6759412-B2 | FOR PRODUCING DRUGS USED FOR THERAPY OF CARDIOVASCULAR DISEASES, STABLE OR UNSTABLE ANGINA PECTORIS, CORONARY HEART DISEASE, PRINZMETAL ANGINA, ACUTE CORONARY SYNDROME, HEART FAILURE, MYOCARDIAL INFARCTION, STROKE, THROMBOSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | disclosed |
| CN-1491208-A | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical | ������ҽҩ�¹�����˾ | 2004-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | CTSA 1724/4885KDM4E 4133/4885ALDH1A1 1000/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | CTSA 1724/4885KDM4E 4133/4885ALDH1A1 1000/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | CTSA 1851/4885KDM4E 1470/4885ALDH1A1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.